CVS Health Corporation $CVS Shares Sold by Empowered Funds LLC

Empowered Funds LLC lessened its position in shares of CVS Health Corporation (NYSE:CVS) by 17.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 132,776 shares of the pharmacy operator’s stock after selling 28,709 shares during the period. Empowered Funds LLC’s holdings in CVS Health were worth $9,536,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in CVS. Caitong International Asset Management Co. Ltd boosted its holdings in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares during the period. Swiss RE Ltd. acquired a new stake in shares of CVS Health during the fourth quarter worth $26,000. Sankala Group LLC bought a new position in shares of CVS Health in the 4th quarter worth about $28,000. Global Trust Asset Management LLC boosted its holdings in shares of CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after buying an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. acquired a new position in shares of CVS Health in the 4th quarter valued at about $28,000. 80.66% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. This represents a 24.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,441,551 shares of company stock worth $323,703,977 over the last three months. Corporate insiders own 0.85% of the company’s stock.

CVS Health Price Performance

Shares of NYSE:CVS opened at $105.21 on Friday. The firm’s 50 day moving average is $101.22 and its two-hundred day moving average is $86.91. The firm has a market capitalization of $134.24 billion, a P/E ratio of 46.35, a PEG ratio of 1.03 and a beta of 0.61. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 52 week low of $61.19 and a 52 week high of $110.68.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same period in the previous year, the firm posted $2.25 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts anticipate that CVS Health Corporation will post 7.46 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be paid a $0.665 dividend. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.5%. CVS Health’s dividend payout ratio is presently 117.18%.

Analysts Set New Price Targets

CVS has been the topic of several research reports. Robert W. Baird increased their price objective on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. TD Cowen upped their target price on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a report on Monday, May 11th. Barclays increased their price target on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. HSBC restated a “hold” rating and set a $103.00 price objective on shares of CVS Health in a research report on Monday, July 6th. Finally, Truist Financial upped their price objective on CVS Health from $108.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Twenty-one research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.67.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts expect CVS Health’s upcoming results to show earnings growth, supported by favorable estimates and recent positive estimate revisions. The outlook reinforces expectations that the company can continue its earnings recovery after reporting quarterly EPS and revenue above consensus in its latest report. CVS Health Earnings Expected to Grow
• Positive Sentiment: UnitedHealth’s second-quarter results—featuring improved margins, a lower medical cost ratio and raised earnings guidance—provide a constructive read-through for managed-care companies including CVS Health, suggesting industry cost pressures may be easing. UnitedHealth Turnaround Signal
• Positive Sentiment: CVS received the overall winner award and four gold awards at the 2026 US Customer Experience Awards, including recognition for AI innovation and consumer-centric culture. The recognition supports management’s efforts to improve customer engagement and digital operations, though it has limited immediate earnings impact. CVS Customer Experience Awards
• Positive Sentiment: CVS expanded its pharmacy offering to include common prescription medications for dogs and cats across approximately 9,000 stores, creating a potential new convenience and prescription-volume opportunity. Pet Medications Available at CVS Pharmacy
• Neutral Sentiment: Health100 earned accreditation for consumer data privacy and security, while CVS settled-related litigation involving X and the World Federation of Advertisers. Both developments may reduce reputational or compliance concerns but are unlikely to materially affect near-term earnings. Health100 Accreditation
• Negative Sentiment: Reports that the Trump administration may discontinue subsidies that help hold down Medicare Part D premiums in 2027 are weighing on health-insurance stocks. The change could increase pricing pressure, membership risk and medical-cost uncertainty for CVS’s Aetna business. Medicare Subsidy Report

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.